240 related articles for article (PubMed ID: 25664920)
1. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
Franke MF; Becerra MC; Tierney DB; Rich ML; Bonilla C; Bayona J; McLaughlin MM; Mitnick CD
Ann Am Thorac Soc; 2015 May; 12(5):674-9. PubMed ID: 25664920
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
3. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
4. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
Kuhlin J; Smith C; Khaemraev A; Tigay Z; Parpieva N; Tillyashaykhov M; Achar J; Hajek J; Greig J; du Cros P; Moore D
Int J Tuberc Lung Dis; 2018 May; 22(5):544-550. PubMed ID: 29663960
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Li D; Hu Y; Werngren J; Mansjö M; Zheng X; Drobniewski F; Hoffner S; Xu B
Antimicrob Agents Chemother; 2016 Sep; 60(9):5159-66. PubMed ID: 27297481
[TBL] [Abstract][Full Text] [Related]
6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
7. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
9. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Ngabonziza JCS; Diallo AB; Tagliani E; Diarra B; Kadanga AE; Togo ACG; Thiam A; de Rijk WB; Alagna R; Houeto S; Ba F; Dagnra AY; Ivan E; Affolabi D; Schwoebel V; Trebucq A; de Jong BC; Rigouts L; Daneau G;
PLoS One; 2017; 12(10):e0187211. PubMed ID: 29088294
[TBL] [Abstract][Full Text] [Related]
10. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
Sun F; Li Y; Chen Y; Guan W; Jiang X; Wang X; Ren P; Li J; Shi J; He G; Wu M; Tang P; Wang F; Sheng Y; Huang F; Zhou Z; Huang H; Hong L; Liu Q; Zhang Y; Zhang W
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578402
[TBL] [Abstract][Full Text] [Related]
11. Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar.
Ei PW; Mon AS; Htwe MM; Win SM; Aye KT; San LL; Zaw NN; Nyunt WW; Myint Z; Lee JS; Aung WW
Tuberculosis (Edinb); 2020 Dec; 125():102013. PubMed ID: 33142220
[TBL] [Abstract][Full Text] [Related]
12. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
Calderón RI; Velásquez GE; Becerra MC; Zhang Z; Contreras CC; Yataco RM; Galea JT; Lecca LW; Kritski AL; Murray MB; Mitnick CD
Int J Tuberc Lung Dis; 2017 Aug; 21(8):894-901. PubMed ID: 28786798
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.
Naluyange R; Mboowa G; Komakech K; Semugenze D; Kateete DP; Ssengooba W
PLoS One; 2020; 15(5):e0232543. PubMed ID: 32413052
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.
Kurbatova EV; Cavanaugh JS; Dalton T; Click ES; Cegielski JP
Clin Infect Dis; 2013 Oct; 57(8):1081-93. PubMed ID: 23840002
[TBL] [Abstract][Full Text] [Related]
18. Characterization of pyrazinamide resistance in consecutive multidrug-resistant
Mansjo M; Werngren J; Hoffner S
Int J Mycobacteriol; 2017; 6(2):156-161. PubMed ID: 28559517
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Che Y; Bo D; Lin X; Chen T; He T; Lin Y
BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Liu W; Chen J; Shen Y; Jin J; Wu J; Sun F; Wu Y; Xie L; Zhang Y; Zhang W
Clin Microbiol Infect; 2018 Sep; 24(9):1016.e1-1016.e5. PubMed ID: 29288021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
